Sermorelin vs tesamorelin: how the two peptides actually differ

Last updated 2026-07-24

What is the basic difference between sermorelin and tesamorelin?

Both drugs are synthetic analogs of growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends to the pituitary gland to make it release growth hormone. Neither is growth hormone itself. That distinction matters more than most marketing copy admits. Sermorelin is a 29-amino-acid fragment that mimics the active portion of natural human GHRH. Tesamorelin is a modified 44-amino-acid GHRH analog with a trans-3-hexenoic acid group added to the N-terminus, which slows its breakdown by the enzyme DPP-4 and gives it a longer active window in the body. That structural tweak is the whole reason tesamorelin exists as a separate drug rather than just being sermorelin under another name. The regulatory history is different too, and it's a useful lens for judging either drug. Tesamorelin was approved by the FDA under the brand name Egrifta in 2010, specifically for reducing excess abdominal fat in HIV patients with lipodystrophy, a specific and well-defined medical problem. Sermorelin had its own approved brand, Geref, cleared for diagnosing and treating growth hormone deficiency. Geref was discontinued by its manufacturer for commercial reasons; it was not pulled for a safety failure. That's a real fact worth having straight, because a lot of online chatter conflates "discontinued" with "banned" or "unsafe," and those are not the same thing. Today, sermorelin is available almost exclusively as a compounded peptide made from bulk drug substance, which puts it in a different regulatory lane than an FDA-approved product like tesamorelin. More on what that means for sourcing below.

How do sermorelin and tesamorelin compare on FDA approval status?

Tesamorelin (Egrifta, later Egrifta SV) is FDA-approved for one specific indication: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. That approval is narrow. It is not approved for general fat loss, muscle gain, athletic performance, or anti-aging use in people without HIV-associated lipodystrophy. Sermorelin's branded predecessor, Geref, was FDA-approved for diagnostic testing of growth hormone deficiency and for treatment of pediatric growth hormone deficiency, per the drug's history in the FDA's own approved-products database ^[1]. That approval no longer has an active branded product behind it. When sermorelin is prescribed today, it's typically made by a compounding pharmacy under a prescription, using bulk sermorelin acetate as the raw material. The FDA maintains lists of bulk drug substances that compounders may legally use under Section 503A and 503B of the Food, Drug and Cosmetic Act ^[2][3]. Whether a specific peptide appears on those lists, and stays there, is worth checking before you commit to a compounded product, since the list is reviewed and can change. The underlying compounding authority itself comes from 21 U.S.C. 353a ^[4]. Bottom line on approval status: tesamorelin has an active, narrow FDA approval. Sermorelin has a lapsed brand approval and now exists mainly as a compounded prescription product. Neither status makes a drug automatically safer or more effective for uses outside what was studied. It just tells you what evidence and oversight actually stand behind the product you'd be getting.

How do sermorelin and tesamorelin compare on effectiveness and evidence?

How do sermorelin and tesamorelin compare on dosing and administration?

Both are given as subcutaneous injections, typically at night, timed to work with the body's natural nocturnal GH pulse. Neither is an oral drug; peptide bonds don't survive the gut, which is why injection is the only practical route for either one. Sermorelin protocols used in compounding practice generally run in the range of roughly 200 to 300 mcg per day, dosed at bedtime, though exact amounts vary by prescriber and by patient factors like weight and goals. Tesamorelin's approved dosing for Egrifta is a fixed 2 mg subcutaneous injection once daily, per its FDA labeling history, a simpler regimen with less room for prescriber-to-prescriber variation because it's tied to an approved product insert rather than an individualized compounding protocol. That difference in dosing structure reflects the deeper difference between the two: tesamorelin's dose was established through the FDA approval process for a specific population, while sermorelin dosing in current practice is set by individual prescribers and compounding pharmacies, since there's no active FDA-approved label to standardize it. If you want a full walkthrough of sermorelin dosing specifically, see the main sermorelin reference page.

Can you stack sermorelin and tesamorelin together?

Some prescribers do combine a GHRH analog with a separate class of peptide called a GH-releasing peptide (GHRP), such as ipamorelin, on the theory that hitting two different receptor pathways gives a stronger combined GH pulse than either alone. That's a different question from stacking sermorelin and tesamorelin together, since both of those are GHRH analogs acting on the same receptor. Layering two drugs that compete for the same receptor doesn't have a clear rationale, and there isn't good published evidence describing outcomes from combining them specifically. If you're weighing a GHRH-plus-GHRP combination protocol rather than a sermorelin-tesamorelin stack, that's covered in more detail in can stack tesamorelin and sermorelin. Talk to your prescriber before combining any peptides; this is exactly the kind of decision that should run through someone who knows your labs and history, not a forum thread.

How do sermorelin and tesamorelin compare on side effects and safety?

Both drugs share the general side effect profile common to GHRH analogs: injection site reactions (redness, itching, mild swelling), headache, flushing, and occasionally dizziness. Because both work by stimulating your own pituitary rather than delivering GH directly, the risk of drastically oversupplying GH is lower than with direct HGH injections, though it isn't zero, and it isn't a reason to skip monitoring. Long-term GH elevation, from any source, has been linked to case reports of unusual complications. One recent case report described anterior cervical osteophyte-related dysphagia (difficulty swallowing caused by bone spur growth in the neck) in a long-term growth hormone user, a reminder that sustained elevation of the GH-IGF-1 axis over years is not something to treat casually ^[10]. That case involved a long-term GH user rather than a GHRH-analog patient specifically, but it's relevant context for anyone thinking about years of GH-axis stimulation from any product. Tesamorelin's studied population (people with HIV-associated lipodystrophy) has its own monitoring considerations, including glucose tolerance, since GH-axis stimulation can affect insulin sensitivity. Anyone using it, on or off label, should have that watched. For sermorelin specifically, a longer look at what's known and not known about extended use is in sermorelin long-term side effects. Contamination and counterfeiting are also real risks in the peptide market broadly; one European surveillance report on falsified biopharmaceutical injectables documented the scale of counterfeit product circulating outside legitimate pharmacy channels ^[11], which is one more argument for sourcing through a licensed pharmacy rather than an unregulated seller.

How do sermorelin and tesamorelin compare to HGH directly?

This is probably the question that actually brought you here, and it deserves a straight answer: sermorelin and tesamorelin are not HGH, and in a head-to-head against direct HGH injections, sermorelin is often the weaker choice if your only goal is maximizing GH and IGF-1 levels as fast as possible. HGH (somatropin) is the hormone itself, injected directly, bypassing your pituitary entirely. It reliably raises IGF-1 and GH markers because there's no biological step it depends on other than absorption. Sermorelin and tesamorelin instead ask your own pituitary to do the work, which means the response depends on how much functioning pituitary tissue and GHRH-receptor sensitivity you still have. In someone with a healthy, responsive pituitary, that can still meaningfully raise IGF-1 ^[6]. In someone whose pituitary is already significantly damaged or aged out of strong GHRH responsiveness, a GHRH analog will underperform direct HGH, sometimes by a wide margin. The tradeoff runs the other direction on safety and physiology. Because sermorelin and tesamorelin rely on the pituitary's own feedback loops, they preserve the natural pulsatile pattern of GH release and carry a built-in ceiling: if GH and IGF-1 rise enough, the hypothalamus and pituitary throttle back the signal. Direct HGH injection overrides that feedback loop entirely, which is part of why direct HGH carries a higher risk of overshoot conditions like insulin resistance, joint and soft tissue swelling, and other classic GH-excess symptoms when misused or overdosed. So the honest framing is this: if you want the strongest, most predictable GH and IGF-1 bump and your pituitary function isn't the concern, direct HGH will get you there more reliably than sermorelin will, but it comes with a materially different (and generally higher) risk profile and it requires a legitimate diagnosis to prescribe responsibly. If you're a reasonable candidate with a working pituitary and you want a gentler, self-regulating approach, sermorelin (or tesamorelin, for its approved indication) is the more conservative starting point, not the more powerful one. Nobody should walk into this expecting sermorelin to match HGH gram for gram; that's not how the mechanism works, and claiming otherwise oversells the drug.

Is tesamorelin stronger than sermorelin?

In terms of molecular design, yes: the added stability against DPP-4 breakdown gives tesamorelin a longer effective window per dose than unmodified sermorelin, and its approved use case (visceral fat reduction in HIV lipodystrophy) reflects a more concentrated, targeted clinical effect in that specific population. But "stronger" isn't a fair one-word answer outside its lane. Tesamorelin was tested and approved for a narrow, specific problem: excess visceral fat in people with HIV-associated lipodystrophy. Its results in that population don't automatically transfer to general fat loss, muscle building, or anti-aging use in people without that condition, because that's not what was studied. Sermorelin's traditional use case, adult-onset GH insufficiency and pediatric GH deficiency diagnosis, is a different target population entirely. If you're asking which one is likely to do more for you personally, the honest answer depends entirely on why you're considering either drug in the first place, and that's a conversation for a prescriber who can look at your labs, not a side-by-side spec sheet.

How are sermorelin and tesamorelin detected in drug testing?

This matters if you're an athlete under a testing program, less so for the average person considering GH-axis therapy for clinical reasons, but it's worth knowing the landscape exists. Both sermorelin and tesamorelin fall into the broader category of GHRH analogs that anti-doping labs actively screen for, and detection science in this space has moved quickly over the past decade. Researchers have published methods using immunoaffinity purification combined with high-resolution mass spectrometry to identify GHRH analogs in both urine and plasma at very low concentrations ^[12][13][14]. Other groups have developed antibody-free, ultrafiltration-based assays capable of detecting these peptides in urine at low picogram-per-milliliter levels ^[15], and newer work has applied nano-liquid-chromatography-orbitrap methods to catch GHRH analogs and their metabolites in urine ^[16]. Stability studies of GHRP and GHRH-related peptides in serum have also been used to build in-house reference standards for these detection methods ^[17]. A recent review specifically covering detection of GHRH synthetic analogs summarized how testing has adapted as new analogs (including modified ones like tesamorelin) have entered the market ^[18], and a broader critical review of peptide and peptide-analog doping in recreational and professional sport walked through how this category has expanded well beyond classic anabolic agents ^[19]. If you're subject to World Anti-Doping Agency testing, both sermorelin and tesamorelin are things to disclose and discuss with a sports medicine physician, not something to assume flies under the radar.

What do sermorelin and tesamorelin cost, and does insurance cover either?

Tesamorelin, as an FDA-approved branded product (Egrifta/Egrifta SV), can be covered by insurance when prescribed for its approved indication, HIV-associated lipodystrophy, though coverage and copay amounts vary by plan and by whether prior authorization is required. Used off-label for anything else, insurance coverage is unlikely and out-of-pocket cost is typically the norm. Sermorelin, since it's compounded rather than sold as an FDA-approved brand, is essentially always a cash-pay product. Pricing varies by compounding pharmacy, dose, and region, and there's no standardized national price the way there is for an approved drug with a listed wholesale acquisition cost. This is one more reason sourcing matters: price alone won't tell you whether a compounded product is legitimate, properly dosed, or free of contamination, and unusually cheap sermorelin from an unverified seller is a red flag rather than a bargain. For a closer look at what legitimate sourcing looks like, see best place to buy sermorelin and sermorelin reviews.

What does the research say about newer or off-label uses of sermorelin?

A few narrower research threads are worth knowing about, mostly so you can spot overhyped claims when you see them. One 2021 paper explored sermorelin as a potentially effective drug for patients with recurrent glioma, a type of brain tumor, based on laboratory findings about its effects on tumor-related pathways ^[20]. That's early-stage, mechanism-level research, not a treatment recommendation, and it has nothing to do with the compounded sermorelin sold for GH support. Older pharmacology work also looked at sermorelin's role in the perinatal period, studying how GH-releasing factor affects maternal and fetal secretion of pituitary and placental growth hormone ^[21]. That's foundational physiology research from decades ago, not a clinical use case for adults today. Neither of these lines of research supports using sermorelin for anti-aging, weight loss, or muscle building in otherwise healthy adults. If you see marketing that stretches early-stage or unrelated research into a broad wellness claim, that's a sign to be skeptical, not a sign of new proven benefit.

How should you decide between sermorelin, tesamorelin, and HGH?

Start with why you're actually looking at any of these. If you have a diagnosed GH deficiency confirmed by proper stimulation testing and bloodwork, that conversation belongs with an endocrinologist, and the choice between a GHRH analog and direct HGH will depend on your specific pituitary function, age, and goals, not on which one has better marketing. If you're looking at tesamorelin specifically because you have HIV-associated lipodystrophy, that's the one condition where the drug has real, approved evidence behind it, and it's worth discussing directly with your HIV care provider. If you're a healthy adult curious about GH-axis support for energy, sleep, or body composition reasons without a diagnosed deficiency, be honest with yourself about the evidence gap. The research base for sermorelin in adult-onset GH insufficiency exists ^[5], but it doesn't extend to general wellness use in people with normal GH levels, and no legitimate source should promise you it does. The place to start either way is a proper lab workup and a conversation with a prescriber who reviews your case rather than sells you a protocol; the sermorelin hub page and sermorelin peptide before and after page are reasonable next reads if you want the fuller evidence picture before that conversation. Where you're ready to move forward, look for a provider-reviewed path that connects you to a licensed pharmacy partner for fulfillment; Sermorelin Co's role in that process is connecting patients to that provider review step, not compounding or manufacturing anything itself.

Frequently asked questions

Is tesamorelin the same as sermorelin?

No. Both are GHRH analogs that stimulate the pituitary to release growth hormone, but they're structurally different molecules. Tesamorelin is a 44-amino-acid analog with a chemical modification that resists breakdown by DPP-4; sermorelin is a shorter, 29-amino-acid fragment of natural GHRH. They also have different regulatory histories and approved uses.

Which is better, sermorelin or tesamorelin?

Neither is universally "better." Tesamorelin has FDA approval specifically for reducing abdominal fat in HIV-associated lipodystrophy. Sermorelin's evidence base centers on adult-onset GH insufficiency and pediatric GH deficiency diagnosis, via its discontinued brand Geref. The right choice depends entirely on the medical problem you're actually treating.

Is sermorelin FDA approved?

Sermorelin's branded version, Geref, was FDA-approved for growth hormone deficiency diagnosis and pediatric treatment, but it was discontinued for business reasons, not a safety recall. Sermorelin sold today comes from compounding pharmacies using bulk drug substance under 21 U.S.C. 353a, not as an FDA-approved finished product.

Is tesamorelin FDA approved?

Yes. Tesamorelin is FDA-approved under the brand names Egrifta and Egrifta SV, specifically for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It is not approved for general fat loss, muscle building, or anti-aging use outside that population.

Can you use sermorelin and tesamorelin together?

There's no established protocol or good published evidence for stacking two GHRH analogs that act on the same receptor. Some prescribers do combine a GHRH analog with a different-class GH secretagogue (a GHRP like ipamorelin), which is a separate strategy. Any combination decision should go through a prescriber reviewing your labs, not a self-directed stack.

Does sermorelin or tesamorelin work as well as HGH?

Neither raises GH and IGF-1 as reliably or as strongly as direct HGH injection, because both depend on your pituitary still responding to GHRH signaling. In someone with a healthy pituitary, sermorelin can meaningfully raise IGF-1, but it won't match HGH's direct, feedback-independent effect, especially if pituitary responsiveness is already reduced.

What is Geref, and why was it discontinued?

Geref was the original FDA-approved brand name for sermorelin, approved for growth hormone deficiency diagnosis and pediatric treatment. It was discontinued by its manufacturer for commercial reasons. It was not withdrawn due to a safety finding, which is an important distinction from drugs pulled for adverse events.

What are the side effects of sermorelin vs tesamorelin?

Both share a similar side effect profile as GHRH analogs: injection site irritation, headache, flushing, and occasional dizziness. Because both stimulate the body's own GH release rather than delivering GH directly, sustained overdose risk is lower than with HGH, though long-term GH-axis stimulation from any source still warrants monitoring, as case reports on GH-related complications illustrate.

Is tesamorelin used off-label for anything besides HIV lipodystrophy?

Yes, some prescribers use tesamorelin off-label for body composition goals in people without HIV-associated lipodystrophy, but that use isn't backed by the same approved trial evidence and isn't typically covered by insurance. Off-label use should be discussed explicitly with a prescriber who can explain what evidence does and doesn't support it.

How is sermorelin dosed compared to tesamorelin?

Compounded sermorelin protocols commonly run around 200 to 300 mcg per day by subcutaneous injection at bedtime, though this varies by prescriber. Tesamorelin's FDA-approved dosing for Egrifta is a fixed 2 mg subcutaneous injection once daily, a simpler regimen because it follows an approved product label rather than individualized compounding.

Does insurance cover sermorelin or tesamorelin?

Tesamorelin can be covered by insurance when prescribed for its approved indication, HIV-associated lipodystrophy, subject to plan rules and prior authorization. Sermorelin, as a compounded product rather than an FDA-approved brand, is almost always cash-pay, with prices varying by compounding pharmacy and region.

How are sermorelin and tesamorelin detected in doping tests?

Anti-doping labs use immunoaffinity purification combined with high-resolution mass spectrometry, and newer antibody-free ultrafiltration methods, to detect GHRH analogs including sermorelin and tesamorelin in urine and plasma at very low concentrations. Detection science in this category has advanced significantly over the past decade as new analogs have entered use.

Is sermorelin safe for long-term use?

Sermorelin's older clinical literature centers on adult GH insufficiency treatment, and it's generally described as working with the body's natural feedback loops rather than overriding them. But long-term data specifically on years of continuous compounded sermorelin use in healthy adults is limited, and monitoring by a prescriber remains the responsible approach rather than open-ended self-use.

Sources

1. FDA, Drugs@FDA approved drug products database: Geref was the FDA-approved brand name for sermorelin, historically approved for growth hormone deficiency diagnosis and treatment
2. eCFR, 21 CFR 216.23 (503A Bulks List): Bulk drug substances eligible for use in 503A pharmacy compounding are governed by a specific FDA list
3. eCFR, 21 CFR 216.24 (503B Bulks List): Bulk drug substances eligible for 503B outsourcing facility compounding are governed by a separate FDA list
4. Cornell Law School, 21 U.S.C. 353a: Pharmacy compounding of drugs including sermorelin is authorized and governed under this federal statute
5. Clinical Interventions in Aging, 2006 (PMID 18046908): Sermorelin has been studied as a physiologic approach to managing adult-onset growth hormone insufficiency
6. American Journal of Men's Health, 2017 (PMID 28830317): Growth hormone secretagogue treatment raised serum IGF-1 levels in hypogonadal men
7. Translational Andrology and Urology, 2020 (PMID 32257855): Growth hormone secretagogues have been studied for a role in body composition management in hypogonadal males
8. Sports Medicine (Auckland, N.Z.), 2026 (PMID 41966639): A review of approved and unapproved peptide therapies for musculoskeletal and athletic performance use found inconsistent safety and efficacy data
9. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): A review of therapeutic peptides in orthopaedics highlighted current applications and evidence challenges facing this drug category
10. Frontiers in Surgery, 2026 (PMID 42465868): A case report described anterior cervical osteophyte-related dysphagia in a long-term growth hormone user
11. Drug Testing and Analysis, 2016 (PMID 26456392): A European surveillance operation documented falsified biopharmaceutical injectables circulating outside legitimate pharmacy channels
12. Analytical and Bioanalytical Chemistry, 2016 (PMID 26879649): Immunoaffinity purification combined with LC-HRMS/MS was used to qualitatively identify GHRH analogs in human plasma
13. Journal of Chromatography A, 2020 (PMID 32971474): Magnetic bead surface functionalities were compared for immunopurification of GHRH analogs prior to mass spectrometry detection
14. Drug Testing and Analysis, 2015 (PMID 26382721): An expanded test method using immunoaffinity purification and LC-HRMS/MS was developed for peptides above 2 kDa
15. Journal of Pharmaceutical and Biomedical Analysis, 2022 (PMID 35298973): An antibody-free, ultrafiltration-based assay can detect GHRH analogs in urine at low picogram-per-milliliter concentrations
16. Journal of Pharmaceutical and Biomedical Analysis, 2026 (PMID 41138283): Nano-liquid chromatography with quadrupole/orbitrap mass spectrometry has been used to analyze GHRH and its analogs in urine
17. Biomedical Chromatography, 2023 (PMID 37688464): Enzymatic and serum stability profiles of GHRP and GHRH-related peptides were characterized to build in-house doping reference standards
18. Drug Testing and Analysis, 2021 (PMID 34665524): Detection methods for synthetic GHRH analogs, including modified variants, have advanced substantially in recent years
19. The Journal of Sports Medicine and Physical Fitness, 2026 (PMID 41880199): A critical review documented the expanding use of peptide and peptide-analog drugs in recreational and professional sport
20. Annals of Translational Medicine, 2021 (PMID 33842627): Early-stage research explored sermorelin as a potentially effective drug for patients with recurrent glioma
21. The Journal of Clinical Endocrinology and Metabolism, 1990 (PMID 2143200): Foundational research examined how GH-releasing factor affects maternal and fetal pituitary and placental growth hormone secretion